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Abstract Postoperative treatments for lung cancer have been evaluated for more than two decades, but
in the majority of the studies no significant and clinically meaningful effect on survival has
been shown. In 1995, a meta-analysis of eight cisplatin-based adjuvant chemotherapy trials
in 1,394 patients with non ^ small cell lung cancer showed a 13% reduction in the risk of death
(P = 0.08). The nonstatistically significant benefit reported in the meta-analysis prompted the
planning of several randomized studies of platinum-based chemotherapy. Three studies
addressed the issue of adjuvant chemotherapy in all the resected stages of non ^ small cell
lung cancer (I-IIIA): the Italian/European studyAdjuvant Lung Cancer Project Italy, the Interna-
tional Adjuvant Lung Cancer study, and the British Big Lung Trial. In contrast to the Interna-
tional Adjuvant Lung Cancer, the Adjuvant Lung Cancer Project Italy and the underpowered
British Big LungTrial failed to prospectively confirm a significant role of adjuvant chemothera-
py in completely resected non ^ small cell lung cancer. In this article, we will discuss the find-
ings of the Adjuvant Lung Cancer Project Italy study in the context of the International
Adjuvant Lung Cancer and British Big LungTrial.
Lung cancer remains the most common fatal malignancy among
men and women in Europe (1) and worldwide (2). In non–
small cell lung cancer (NSCLC), which represents >80% of all
newly diagnosed cases of lung cancer, the main curative
therapeutic approach for early disease (stage IA-IIB) is surgery.
Unfortunately, these cases represent only a minority (20-25%) of
all cases of NSCLC. The rationale for use of systemic therapy in
completely resected NSCLC is based on follow-up studies after
radical resection that have shown the predominance of distant
failures over local recurrences and on clinical and pathologic
evidence of early microdissemination of the disease at the time of
surgery. Long-term survival in NSCLC following surgical
resection is stage related, but even in stage IA one-third of
patients will relapse and die of their disease within 5 years (3, 4).
Postoperative treatments, including chemotherapy, radiother-
apy, or both, have been evaluated for more than two decades,
and in the vast majority of the studies, no significant and
clinically meaningful effect on survival has been shown. In 1995,
a meta-analysis done in different subgroups of NSCLC patients
receiving chemotherapy overviewed eight cisplatin-based adju-
vant chemotherapy trials in 1,394 patients and found a 13%
reduction in the risk of death, which was close to the borderline
of statistical significance (P = 0.08). Similarly, there was a 6%
reduction in the risk of death in patients treated with
postoperative cisplatin-based chemotherapy compared with
patients who received only postoperative radiotherapy
(P = 0.46). On the other hand, adjuvant chemotherapy with
long-term alkylating agents was significantly detrimental (5).
These findings failed to have an effect on clinical practice, not
because the absolute gain was too small but because such an
estimate was still imprecise, ranging from a 1% detriment to a
10% benefit. In addition, the heterogeneity of surgical proce-
dures and the differences in the staging modalities strongly
limited the applicability of the results of this meta-analysis.
However, the nonstatistically significant benefit in 5-year
survival reported in the NSCLC meta-analysis generated enough
enthusiasm to prompt the planning of several randomized
adjuvant studies, all platinum-based chemotherapy (with or
without thoracic radiotherapy), in completely resected NSCLC
stages I, II, and IIIA. Most of these studies have been recently
presented and published.
Among this last generation of randomized studies, only three
addressed the issue of adjuvant chemotherapy in all resected stages
of NSCLC (stages I-IIIA): the Italian/European study Adjuvant
Lung Cancer Project Italy (ALPI; ref. 6), the International Adjuvant
Lung Cancer (IALT) study (7), and the British Big Lung Trial (8).
The latter was clearly underpowered to look at differences in
survival in the range of the 5% indicated by the meta-analysis,
whereas the other two (ALPI and IALT) were adequately sized to
look at this slim difference. Unfortunately, IALT enrolled only
56% of the original sample size (against 92% of the ALPI),
increasing the possibility of a type I error.
www.aacrjournals.org Clin Cancer Res 2005;11(13 Suppl) July1, 20055011s
Authors’Affiliation: University of Turin, Department of Clinical and Biological
Sciences, S. Luigi Hospital, Thoracic Oncology Unit, Turin, Italy
Grant support: Associazione Italiana per la Ricerca sul Cancro and Consiglio
Nazionale delle Ricerche-Applicazioni Cliniche della Ricerca Oncologica.
Presented at the International Conference on Early-Stage Lung Cancer :
New Approaches to Evaluation and Treatment, October 1-2, 2004, Cambridge,
Massachusetts.
Requests for reprints: Giorgio V. Scagliotti, University of Turin, Department of
Clinical and Biological Sciences, S. Luigi Hospital, Thoracic Oncology Unit,
Regione Gonzole 10, 10043 Turin, Italy. Phone: 39-11-9026-414; Fax: 39-11-
9038-616; E-mail: giorgio.scagliotti@unito.it.
F2005 American Association for Cancer Research.
Cancer Research. 
on February 7, 2019. © 2005 American Association forclincancerres.aacrjournals.org Downloaded from 
ALPI Study: Patients andMethods
In the ALPI study, 66 Italian centers were involved starting April
1995; an additional 5 European centers outside Italy and affiliated
with the European Organization for Research and Treatment of
Cancer Lung Cancer Cooperative Group joined the study at a later
time. In this study, patients who had undergone complete resection
of pathologically documented stage I, II, or IIIA NSCLC were eli-
gible. Lobectomy or pneumonectomy was strongly recommended;
however, more limited resections, although pathologically completed,
were allowed. The International Union Against Cancer staging system
for lung cancer used at the time of the study served as a guide to
stage patients. Lymph node levels were defined according to the
criteria of the American Thoracic Society (9).
Surgical procedures for mediastinal staging and treatment included
either a complete dissection of mediastinal lymph nodes at levels 4, 7,
and 10 during right-sided thoracotomy and at levels 7 and 5 or 6 or
both during left-sided thoracotomy or a systematic sampling of
representative lymph nodes at the specified levels. Additional eligibility
criteria included adequate bone marrow reserve (WBC count z3.5 
109/L, platelets z120  109/L, hemoglobin z10 g/L, and hematocrit
z30%), liver and renal function (creatinine <1.5 times the upper
normal limits), and a postoperative FEV1 value >1.2 L.
All eligible patients were to be randomized within 42 days after
surgery to receive either the MVP regimen (mitomycin 8 mg/m2, day 1;
vindesine 3 mg/m2, days 1 and 8; and cisplatin 100 mg/m2, day 1, every
3 weeks for three cycles) or no chemotherapy. The study design was
fully reported in the original report (6). Randomization was done
centrally; stratification included pathologic tumor and node descriptors
according to the tumor-node-metastasis staging system, investigational
center, and intended radiotherapy.
Patients who experienced progressive disease or unacceptable
toxicity, or who did not receive chemotherapy for 6 weeks from the
time of the last treatment, were discontinued from the study. The
second and third cycles of chemotherapy were administered every
3 weeks only if patients fully recovered from the toxicities of the
previous cycle of therapy; otherwise, chemotherapy was delayed
1 week, and in any persistent grade 2 toxicity, a 25% dose reduction
was planned on day 28. For any higher toxicity grade, the next cycle
was further delayed 1 week. Toxicity was graded according to WHO
criteria (10).
Adjuvant radiotherapy was left to the policy of the participating
centers and, if given, it was planned by stage at the start of the study;
in the experimental arm, radiotherapy initiated 3 to 5 weeks after
the last MVP treatment, and in the control arm 4 to 6 weeks after
radical surgery. In both arms, total radiotherapy dose was 50 to 54 Gy
(2 Gy/daily fraction, 5 days a week) over 5 to 6 weeks. Radiotherapy
treatment to the clinical target volume was administered through two
or three anteroposterior, posteroanterior, lateral, or oblique fields. In
case of documented extracapsular invasion of any nodal station, an
additional 6 Gy dose was specifically delivered. Acute and late
radiotherapy toxicity was graded according to Radiation Therapy
Oncology Group criteria (11).
Once patients were off the protocol therapy (chemotherapy and/or
radiotherapy), they were monitored for assessment of disease status
every 3 months for 2 years, every 6 months during the third year, and
annually thereafter. Monitoring consisted of clinical examination as
well as chest radiography done every 6 months for 2 years and once a
year thereafter. Patients were flagged with the national death registry.
Statistical Plan and Analysis
The primary end point was overall survival (defined as death
from any cause). Secondary end points were progression-free
survival (defined as the time to the earliest recurrence or death
from any cause) and toxicity of chemotherapy. The sample size
was calculated to show a 20% relative reduction of mortality
induced by adjuvant chemotherapy; with a 80% power and a
5% significance (two-sided) level, 535 events were required.
Based on these estimates and the expected recruitment rate, it
was estimated that f1,300 patients would be needed to
complete the study. The study was prematurely closed after
having included 93% of the planned sample size. This decision
was taken due to a lower accrual rate during the last 6 months
of the trial; however, the follow-up time was prolonged to reach
the originally planned number of events. A 20% relative
reduction in mortality hazard ratio (HR) translates into
absolute improvements in the probability of surviving 5 years
of f7% to 8% over a wide range of possible survival rates in
the control group (35-55%).
The data were analyzed for overall survival in all randomized
patients (including protocol violators) on an intention-to-treat
basis using the log-rank test without adjustment for prognostic
factors. Additional analyses were done with the Cox propor-
tional hazards model, adjusted for baseline characteristics. A
Cox model was also developed to assess the effect of the
molecular prognostic factors investigated. Data monitoring and
quality control procedures were set in place to ensure the
quality of the information collected by the participating centers.
These included random site visits and source validation
procedures. An independent data monitoring committee was
set up to check the progress of the trial.
Molecular Prognostic Factors Subproject
In selected centers, tumor tissue samples were centrally
collected and evaluated for the presence/absence of K-ras
mutation and for the degree of positivity to p53 and Ki-67
immunostaining. Paraffin-embedded, formalin-fixed speci-
mens from surgically removed tumors were used to assess
p53 and Ki-67 status by immunohistochemistry [Ab-2 (Onco-
gene Sciences, Manhasset, NY) and MIB-1 (DAKO, Glostrup,
Denmark); refs. 12, 13]. Conditions for the PCR and the
detection of point mutations for codon 12 K-ras using
mutation-specific oligonucleotides were done according to
procedures published previously, and the results were scored
as positive or negative (14).
Results
Over a 5-year enrollment period, a total of 1,209 patients
(1,086 from the Italian centers and 123 from European
Organization for Research and Treatment of Cancer Lung
Cancer Cooperative Group) were enrolled in the study, 606
allocated to chemotherapy and 603 to control arm. Thirteen
patients were excluded from the analysis due to eligibility
criteria violations (4 in MVP and 9 in the control arm). All the
cases from one center (108 cases, 54 in the MVP arm and 54 in
the control arm) were excluded from the final analysis because
of serious concerns about data integrity. The analysis thus
included 1,088 patients, 548 in the chemotherapy arm and 540
in the control arm. Patient characteristics are reported in
Table 1. Data about treatment compliance indicate that 69%
completed the MVP treatment, half of them with some dose
adjustment or omission of the planned regimen, mainly
concerning vindesine administration on day 8. In total, 22%
stopped MVP treatment early, either for toxicity or for patient
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refusal. Chemotherapy was never started in an additional 48
(9%) patients, mainly following consent withdrawal. Regarding
those patients in whom sequential radiotherapy was planned, it
was completed by 65% of the patients in the MVP arm and by
82% in the control group.
Hematologic toxicity was the most common adverse effect in
the MVP arm, with grade 3 and 4 neutropenia occurring in 16%
and 12% of patients, respectively. During sequential radiother-
apy, grade 3 and 4 hematologic toxicity were infrequent (2% in
the MVP arm and 3% in the control arm), and esophagitis
grade 2 to 3 was the most commonly reported adverse effect
(16% in the MVP arm and 15% in the control arm). One
patient in the control arm experienced grade 4 esophagitis
during radiotherapy. Grade 2 to 3 acute pneumonitis was
recorded in 6% in the MVP arm and 9% in the control arm,
whereas grade 4 acute pneumonitis was seen in two patients in
the control arm. There were 10 treatment-related deaths during
the study (3 in the MVP and 7 in control arm). The most
common cause of death was cancer progression, accounting for
71% of the causes of death, followed by nonneoplastic causes
(16%) and by unknown causes (9%); deaths due to a second
primary cancer or treatment-related cancer were documented in
11 patients (MVP = 5 and control = 6) and 10 patients (MVP =
3 and control = 7), respectively.
At the time of the final analysis, 456 (42%) patients were
alive without evidence of disease and 64 (6%) were alive with
recurrent disease. After a median follow-up time of 64.5
months, differences in progression-free survival (HR, 0.89;
P = 0.144) and overall survival (HR, 0.96; P = 0.585) were not
statistically significant. Figures 1 and 2 represent progression-
free and overall survival by stage: no significant interaction
between treatment and stage of disease emerged. It is
remarkable to observe that in the subgroup of patients with
stage II NSCLC, although the HR was not statistically
significant, a 10% benefit at 5 years for chemotherapy-treated
patients was reported for overall survival as well as for
progression-free survival.
In the multivariate analysis for baseline and treatment
characteristics, only stage of the disease and, to a lesser
extent, gender emerged as independent prognostic factors
(Table 2). The ‘‘per protocol’’ analysis to compare overall
survival among patients receiving all the planned three cycles
of chemotherapy with that of patients who underwent no
adjuvant therapy showed no statistically significant difference
between the two groups (HR, 0.86; 95% confidence interval,
0.71-1.04).
In the molecular prognostic factors substudy, 38% of the
primary tumors were analyzed for p53 and Ki-67 expression;
50% and 62% of tumor specimens were positive for p53 and
Ki-67, respectively, in >25% of examined cells. No correlation
with stage, histology, and p53 or Ki-67 expression was found
even when several cutoff points were considered for positivity.
K-ras mutation analysis was assessed only in adenocarcinoma
and large cell carcinoma specimens because a preliminary
analysis done in the first 50 cases of squamous cell carcinoma
revealed the presence of a point mutation in only 2% of tumor
samples. In all, 117 cases were analyzed, and an additional 23
cases were not successfully amplified. Point mutations at exon 1
were detected in 22% of the cases.
Discussion
The ALPI trial was the first large, prospective adjuvant study
designed to detect reasonably small differences in survival and
in the range of those reported by the NSCLC meta-analysis. In
addition, it was the first large-scale adjuvant trial in lung cancer
that successfully enrolled several patients very close to that
originally planned. Subsequently, IALT, another large random-
ized study, aimed to determine the effect on overall survival of a
chemotherapy regimen that included cisplatin (80-120 mg/m2)
and either a Vinca alkaloid (vindesine 3 mg/m2/wk, vinblastine
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Table 1. Selected patient, disease, and treatment
characteristics [n (%) of patients]
Characteristics MVP Control
Male 472 (86) 465 (86)
Median age (y) 61 61
Range 33-76 37-76
Pathologic stage
I 216 (39) 207 (38)
II 172 (31) 183 (34)
IIIA 160 (29) 150 (28)
T1 118 (22) 100 (19)
T2 345 (63) 360 (67)
T3 85 (16) 80 (15)
N0 257 (47) 254 (47)
N1 154 (28) 151 (28)
N2 137 (25) 135 (25)
Histology
Squamous 278 (51) 262 (49)
Adenocarcinoma 196 (36) 206 (38)
Large cell carcinoma 27 (5) 31 (6)
Bronchoalveolar carcinoma 23 (4) 20 (4)
Others 24 (4) 21 (4)
Type of surgery, pneumonectomy 134 (24) 140 (26)
Lymphnode dissection, complete 313 (57) 290 (54)
Planned radiotherapy 238 (43) 232 (43)
Fig. 1. Progression-free survival by stage.
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4 mg/m2/wk, or vinorelbine 30 mg/m2/wk) or etoposide (100
mg/m2/d, 3 consecutive days) compared with no chemother-
apy after complete surgical resection in patients with stage I, II,
or III NSCLC. This trial showed a statistically significant effect
of adjuvant chemotherapy on disease-free and overall survival
rates with an absolute survival benefit at 5 years of 5.1% (P =
0.003) and 4.1% (P = 0.03), respectively (7). The planned
number of patients was 3,300 to observe a 5% survival
difference at 5 years (50-55%). The study started in 1995,
and in December 2000, after enrollment of 1,867 patients, the
study was closed due to slow accrual. The median follow-up
was 56 months. Compliance with chemotherapy was good:
74% of patients received at least 240 mg/m2 cisplatin. Only
23% of patients on the chemotherapy arm experienced grade 4
toxicity.
In clinical trials in which a long follow-up is undertaken, the
difference between treatments may depend on the follow-up
time. That implies that in the early phase of the study there is
the potential for a biased estimate of the treatment effect. In the
IALT study, the accrual was prematurely interrupted when
<60% of expected patients had been enrolled. The follow-up
continued untilf65% of expected events had been observed. If
the study was continued until the planned number of events
was reached, the conditional power to detect, under the null
hypothesis, a statistically significant difference would have been
<50%. Moreover, the adoption of a Bayesian approach, which
may be appropriate for interpreting results when anticipated
analysis seems to be indicating a positive treatment effect,
would have suggested prolonging the follow-up.
In both ALPI and IALT, relapse and recurrence of the
neoplastic disease accounted for the main cause of death; more
relevantly, in both arms of the ALPI study, >40% of patients had
brain relapses. Another common feature to both trials was the
suboptimal compliance to adjuvant chemotherapy, with 8% to
9% of patients never starting chemotherapy and 26% to 31% of
patients receiving less than the three planned courses of
treatment, which compromised the relative dose intensity. In a
comparative analysis of IALT and ALPI, the ability to delivery
chemotherapy did not differ dramatically when a doublet
combination was used instead of a triplet combination. Poor
therapeutic compliance may be related to the longer postoper-
ative recovery period needed by lung cancer patients compared
with breast cancer patients, and, secondly, to a negative selection
bias in both studies (in the ALPI and IALT studies, 26% and 35%
of patients received pneumonectomies, a percentage far exceed-
ing the normal pneumonectomy rate in any surgical series).
Data regarding adjuvant chemotherapy in a subgroup of
surgically resected patients enrolled in the large British Big Lung
Trial have been recently reported. In this trial, 368 patients were
randomized to receive cisplatin-based doublets (38%) or triplets
(62%): the reported HR for overall survival was 1.02, but the
limited sample size, the quality of surgery, and the limited
follow-up period greatly reduce the power of the information
provided (8). The results of another large platinum-based
adjuvant trial are still awaited. In the Adjuvant Navelbine
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Fig. 2. Overall survival by stage.
Table 2.Multivariate analysis for clinical andmolecular prognostic factors (adjusted by stage)
Overall survival Progression-free survival
HR (95% confidence interval)
P
HR (95% confidence interval)
P
Clinical variables
Age (5-y interval) 1.06 (1.00-1.12) 0.062 1.04 (0.99-1.10) 0.149
Stage
II vs I 2.01 (1.62-2.49) 0.0001 1.88 (1.54-2.30) 0.0001
III vs I 3.19 (2.59-3.93) 2.94 (2.39-3.53)
Histology
Squamous vs other 0.87 (0.73-1.03) 0.112 0.84 (0.72-0.99) 0.037
Gender
Male vs female 1.33 (1.02-1.72) 0.034 1.19 (0.94-1.51) 0.150
Complete dissection vs sampling 0.88 (0.75-1.04) 0.135 0.86 (0.74-1.01) 0.068
MVP vs control 0.95 (0.81-1.12) 0.559 0.88 (0.76-1.03) 0.115
Molecular variables
p53 (n = 387) 1.03 (0.98-1.08) 0.30 1.02 (0.97-1.06) 0.49
Ki-67 (n = 395) 1.42 (0.82-2.47) 0.63 1.04 (0.98-1.11) 0.16
K-ras (n = 108) 1.02 (0.95-1.08) 0.20 1.25 (0.73-2.14) 0.41
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International Trial Association study, patients with completely
resected NSCLC were randomized to chemotherapy, which
consisted of four cycles of cisplatin at 100 mg/m2 every 4 weeks
and 16 cycles of vinorelbine at 30 mg/m2/wk or observation
only. In this study, 831 patients were included between October
1994 and December 2000. Data are to be reported in early 2005.
More recently, the results of two randomized studies
conducted in selected patient populations with resected NSCLC
(Cancer and Leukemia Group B and NCIC-JBR.10 trials) were
reported for the first time. Both studies were designed in the
mid-1990s to compare adjuvant carboplatin/paclitaxel (Cancer
and Leukemia Group B 9633 study; ref. 14) or cisplatin/
vinorelbine (NCIC-JBR.10 study; ref. 15) with no adjuvant
therapy for patients with completely resected stage IB (Cancer
and Leukemia Group B trial) or completely resected stage IB or
II disease (NCIC-JBR.10) NSCLC. Cancer and Leukemia Group
B 9633 showed a remarkable improvement in overall survival
in the adjuvant chemotherapy arm compared with the no-
treatment group (12% at 4 years; ref. 14). The magnitude of
benefit of the use of adjuvant carboplatin/paclitaxel was
substantially greater than one might have predicted based on
IALT and the meta-analysis, and considering the available data,
an overestimation of the treatment effect seems possible. Most
notably, the delivery of chemotherapy was excellent and nearly
85% of patients in the treatment group received four cycles or
more of chemotherapy (14). It could be argued that the positive
results were due to a uniform patient population, a regimen
that was well tolerated and nontoxic, and the fact that such a
high fraction of patients were able to get all four cycles of
therapy. However, it should be remembered that the median
follow-up time is only 34 months, and on both survival curves,
there is still a large number of censored patients.
NCIC-JBR.10 study randomized 482 patients with completely
resected stage IB or II NSCLC either to observation or to four
cycles of cisplatin/vinorelbine. The cisplatin was given on days 1
and 8, which allowed for better dose intensity. Overall survival
was significantly prolonged in the treatment arm (94 versus 73
months; P = 0.011), as was recurrence-free survival (not reached
versus 46.7 months; P = 0.0003) and 5-year survival (69% versus
54%). In contrast to the Cancer and Leukemia Group B study,
this regimen was less well tolerated with no deaths due to toxicity
but with grade 3 to 4 neutropenia in 73% and febrile
neutropenia in 6% of patients. Compliance was lower: 34% of
the patients did not start or received only one cycle of
chemotherapy; among reasons for going off treatment, patient
refusal accounted for 30% and drug toxicity for 12% of the cases
(16). These toxicity and compliance issues partially limit the
applicability of such treatment in the daily practice.
Why were these two studies largely positive, exceeding the
5% benefit hypothesized by the meta-analysis and confirmed
by the IALT study? Several potential confounding factors
should be taken into consideration. Firstly, all these adjuvant
studies enrolled a highly selected patient population that may
not be representative of the general population of completely
resected NSCLC patients. Secondly, in many of these studies,
no information is available about the proportion of patients
who during surgical resection underwent systematic nodal
dissection or mediastinal lymph node sampling. In a recent
randomized clinical study, systematic nodal dissection was
found to significantly influence survival in every stage of
resectable NSCLC (17). Thirdly, lung cancer patients fre-
quently suffer from comorbidities, including chronic obstruc-
tive pulmonary disease and cardiovascular diseases, which
were found to significantly affect survival (18, 19). Addition-
ally, an imbalance in the proportion of patients who quit
smoking after radical surgery may potentially account for
survival differences as shown in a study of 273 pathologic
stage I NSCLC patients where the amount of smoking
exposure was found to be a highly significant predictor of
overall survival (20).
Taking into account the meta-analysis data, the nonpositive
outcome of the ALPI study, and the marginally positive results
reported by IALT study, coupled with the two largely positive
adjuvant studies recently presented, how can we move forward?
A new meta-analysis that will consider the results of all these
recently presented studies would undoubtedly be the next step:
this task, already planned, will need to carefully consider all, or
at least most, of the potential confounding factors that may
jeopardize the assessment of the biological effect of adjuvant
chemotherapy in completely resected NSCLC.
Open Discussion
Dr. Thomas Lynch: Dr. Wood, thoughts from your dis-
cussion at ASCO regarding the ALPI trial? In the light now of
some newer data, what is your view of adjuvant chemotherapy?
Dr. Douglas Wood: I think that the ALPI data, while they
were the best at the time it was reported, have been somewhat
trumped by new information from additional trials. The data
from the IALT study dramatically changed the tone of the
discussion from one of ‘‘does it have value’’ to ‘‘it works, but in
which patient populations?’’ It’s now an effort to try to optimize
chemotherapy’s value rather than to say it doesn’t have value.
Dr. Bruce Johnson: I think the data are more consistent than
disparate, in that all these data are pretty consistent in identifying
the subsets of patients for whom adjuvant chemotherapy works.
It appears that adjuvant chemotherapy doesn’t help patients
with very early stage I disease. It may help squamous cell
carcinomas less than adenomacarcinomas, but that is specula-
tion: there are no data. It becomes complicated, as was shown in
the ECOG trial, when you try to do adjuvant therapy for node-
positive patients. It is harder to interpret those data.
Dr. Jeffrey Bogart: You implicated radiotherapy in not seeing
a benefit in certain populations in ALPI. Did you do a
multivariate analysis, looking at radiotherapy as actually
detrimental to those patients?
Dr. Scagliotti: We did, and at least in the multivariate
analysis, radiotherapy was not detrimental. When you are
looking at the IALT and ALPI trials, which are the only trials
that looked at the whole population of completely resected
patients, one clear difference is that more patients received
adjuvant radiotherapy in the ALPI than in the IALT. I am trying
just to offer an explanation as to why one study was negative
and the other one was positive.
Dr. Bogart: If you look at the analysis from all patients who
had planned radiotherapy, they had actually a greater
chemotherapy benefit than patients who did not have planned
radiotherapy. I don’t think it’s a valid assumption that there is a
negative effect of radiotherapy. I think it’s a valid observation.
Dr. Lynch: But, you know, we oncologists always blame the
radiation. No matter what the circumstance is, we find a way to
blame the radiation.
www.aacrjournals.org Clin Cancer Res 2005;11(13 Suppl) July1, 20055015s
Italian/European Experiencewith Adjuvant Therapy
Cancer Research. 
on February 7, 2019. © 2005 American Association forclincancerres.aacrjournals.org Downloaded from 
Dr. Bogart: We are supposed to clear that up at this
conference.
Dr. Nick Thatcher: Why are we actually excluding stage IIIA
patients in most of these studies?
Dr. Scagliotti: It is always complicated to reach agreement on
what is radically resected from the oncologist’s viewpoint and
what is radically resected according to the thoracic surgeon. With
stage IB and II, when you are dealing with pathologic TNM
staging, you are more certain of having a homogenous
population.
Dr. Lynch: Question for Dr. Shaw: we saw the data that Dr.
Scagliotti presented, suggesting K-ras predicted inferior outcome.
Do you think there will come a time when we define disease by
its molecular profile as opposed to thinking more narrowly in
terms of adenocarcinoma versus squamous versus small cell?
Dr. Alice Shaw: Yes, right now we’re discussing three
markers, p53, K-ras , and Ki-67, but in the future, we envision
what has been called personalized molecular medicine where
you actually look at a number of different genetic alterations
(or even genetic polymorphisms) that contribute, for example,
to a patient’s tumor’s sensitivity or lack of sensitivity to
radiation or certain chemotherapies.
Dr. Scagliotti: It is relatively easy to talk around a table among
an audience of 50 investigators, but there is not an easy way to do
these kinds of studies because you need money and you need to
convince pathologists to give you the tissue samples.
Dr. David Gandara: There is an interesting paradigm that is
emerging regarding tobacco-related lung cancer and lung
cancers that occurs in never smokers. The K-ras mutation and
the EGFR mutations, in most people’s work, are largely
mutually exclusive. In other words, they do not occur together.
When we’ve analyzed our SWOG database, we’ve found two
patients who have EGFR mutations, who also have K-ras
mutations. The interesting thing is, they are unusual K-ras
mutations. They are not the ones that are highly associated with
tobacco carcinogenesis.
Dr. Lynch: But if you look at the fact that K-ras mutations are
30%, EGFR mutations is 13%, odds alone are going to say there
is not going to be that many, there might be 2%, 3%, 4% that
are going to have them both. It may just be a statistical
aberration as opposed to a biologic aberration.
Dr. Tyler Jacks: There are plenty of examples of nonmean-
ingful patterns in molecular genetics of cancer, where one does
see segregation of mutations based on larger groups. The
pathways are clearly related and may in the end activate the
same downstream target, and we’ll be able to piece it out. We
are building a comparable mouse model with the same EGFR
mutations, so we’ll be able to do a side-by-side comparison
with the K-ras model and compare biologies, adding the two
mutations together to see if it makes any difference in the cells.
Dr. Johnson: There are two articles of over 1,000 patients
that say there is no overlap between K-ras and EGFR mutations
in patient tumors (21, 22). There will almost certainly be some,
especially in special populations, but it certainly is not
common.
Dr. Scagliotti: Our biological studies were done 7 years ago,
at the time of surgery. So, we did the analysis in a 6-month
period after surgery completely blinded for any survival data. The
value of prospective studies are much higher than any retrospec-
tive study.
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